삼양바이오팜

0120G0KOSPI의약품 제조업

49.3 / 100

Reference Date: 2026-07-24

Financial Score17.5 / 40

News Sentiment17.8 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 8.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samyang Biopharm operates in three main business segments: medical devices, pharmaceuticals, and new drug development. Key products include biodegradable surgical sutures and hemostatic agents in the medical device sector, and anticancer drugs for solid and blood cancers in the pharmaceutical sector. The company is developing gene therapy platforms (SENS) for new drug research, with medical devices contributing 62.5% of total revenue.

Number of Employees

407people

Average Salary

79.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

140.64Industry Average 11.230.0Point

12.5x industry avg (risky)

PBR

1.34Industry Average 0.811.0Point

1.7x industry avg (risky)

ROE

—Industry Average 4.013.5Point

Debt Ratio

1.29Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

5 totalPositive 3Neutral 1Negative 1Average Sentiment Score 71

Neutral
"팬데믹 또 오면"…K백신 100일 내 만들겠다는 한국비엠아이 [인터뷰...
인터뷰에서 한국비엠아이의 오픈 이노베이션 전략이 강조되었으나, 직접적인 삼양바이오팜의 영향은 제한적입니다.
Positive
[바이오 USA]삼양바이오팜, 차세대 약물전달 플랫폼 '센스'로 시장 ...
삼양바이오팜의 차세대 약물전달 플랫폼 '센스'가 바이오 USA에서 다수의 파트너링을 통해 시장 경쟁력을 강화했다.
Positive
"차세대 약물전달기술 승부수 … 내년 첫 신약 임상 신청 목표"
삼양바이오팜이 차세대 약물전달 기술을 통해 새로운 신약 임상 신청을 내년에 목표로 설정하며 성장 가능성을 높이고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 42,300Won52-week high 142,70052-week low 30,200

1-month return1.0Point

1m -8.74% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral지속가능경영보고서등관련사항(자율공시)2026-06-25